Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression
Open Access
- 22 February 2013
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 123 (3), 1157-1175
- https://doi.org/10.1172/jci63672
Abstract
Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis of cooperation between these genetic alterations is unknown. Here, we show that SPRY2 deficiency alone triggers activation of AKT and ERK, but this is insufficient to drive tumorigenesis. In addition to AKT and ERK activation, SPRY2 loss also activates a PP2A-dependent tumor suppressor checkpoint. Mechanistically, the PP2A-mediated growth arrest depends on GSK3β and is ultimately mediated by nuclear PTEN. In murine prostate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including metastasis. Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel tumor suppressor checkpoint. Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN and/or PP2A subunits in human prostate cancer. This underlines the cooperation between SPRY2 deficiency and PTEN or PP2A inactivation in promoting tumorigenesis. Overall, we propose SPRY2, PTEN, and PP2A status as an important determinant of prostate cancer progression. Characterization of this trio may facilitate patient stratification for targeted therapies and chemopreventive interventions.Keywords
This publication has 43 references indexed in Scilit:
- Cooperative Phosphorylation of the Tumor Suppressor Phosphatase and Tensin Homologue (PTEN) by Casein Kinases and Glycogen Synthase Kinase 3βPublished by Elsevier BV ,2005
- Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancerOncogene, 2005
- Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesisOncogene, 2004
- PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cellsOncogene, 2004
- Pten Dose Dictates Cancer Progression in the ProstatePLoS Biology, 2003
- Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.2003
- Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vectorEMBO Reports, 2003
- Regulation of β-Catenin Signaling by the B56 Subunit of Protein Phosphatase 2AScience, 1999
- Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expressionProceedings of the National Academy of Sciences of the United States of America, 1998
- sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila AirwaysCell, 1998